Akebia Therapeutics (AKBA) Cash from Financing Activities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash from Financing Activities data on file, last reported at -$926000.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$926000.0, down 101.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 102.77% YoY), and the FY2025 annual result was $72.9 million, up 46.84% from the prior year.
• Cash from Financing Activities advanced to -$926000.0 in Q1 2026 per AKBA's latest filing, from -$4.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $74.9 million in Q1 2025 and troughed at -$32.9 million in Q3 2022.
• A 5-year average of $6.5 million and a median of $50000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities tumbled 128900.0% in 2023, then soared 2346.0% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$1000.0 in 2022, then plunged by 128900.0% to -$1.3 million in 2023, then surged by 1830.62% to $22.3 million in 2024, then plunged by 121.72% to -$4.8 million in 2025, then soared by 80.9% to -$926000.0 in 2026.
• Business Quant data shows AKBA's Cash from Financing Activities at -$926000.0 in Q1 2026, -$4.8 million in Q4 2025, and $1.1 million in Q3 2025.